Skip to main content
TipRanks
Go Ultimate75% OFF

Sarepta Therapeutics (AB3A) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

AB3A Analyst Ratings

Hold
18Ratings
3Buy11Hold4Sell
Based on 18 analysts giving stock ratings to Sarepta Therapeutics in the past 3 months

AB3A Stock 12 Month Forecast

CHF17.99▲(0.00% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is CHF 17.99 with a high forecast of CHF 31.74 and a low forecast of CHF 4.18. The average price target represents a ― change from the last price of ―.
Highest Price TargetCHF31.74Average Price TargetCHF17.99Lowest Price TargetCHF4.18

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for CH:AB3A
Price TargetArticle
Piper SandlerCHF16.71hold―Reiterated11/13/26
Deutsche Bank CHF15.04hold―Upgraded11/10/26
BarclaysCHF16.71hold―Reiterated11/09/26
CitiCHF10.86sell―Reiterated11/09/26
Robert W. BairdCHF16.71→CHF15.04hold―Reiterated11/06/26
H.C. WainwrightCHF4.18sell―Reiterated11/06/26
Wells FargoCHF31.74buy―Reiterated11/06/26
OppenheimerCHF29.24buy―Reiterated11/06/26
WedbushCHF29.24buy―Reiterated11/06/26
Morgan StanleyCHF20.88hold―Assigned11/06/26
Bank of America Securities―sell―Reiterated11/06/26
RBC CapitalCHF14.20→CHF15.04hold―Reiterated11/05/26
Cantor FitzgeraldCHF17.54hold―Reiterated11/05/26
TD CowenCHF14.20hold―Reiterated10/21/26
Leerink Partners Analyst forecast on CH:AB3AUnknown AnalystNot RankedLeerink PartnersCHF16.71hold―Reiterated10/15/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
IMUXImmunic
QUITAchieve Life Sciences
COGTCogent Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

3 Months
Mitchell Kapoor
Mitchell KapoorH.C. Wainwright
Success Rate16/19 ratings generated profit
84%
Average Return
+12.34%

Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 84.21% of your transactions generating a profit, with an average return of +12.34% per trade.

1 Year
Mitchell Kapoor
Mitchell KapoorH.C. Wainwright
Success Rate18/19 ratings generated profit
95%
Average Return
+23.08%

Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +23.08% per trade.

2 Years
Mitchell Kapoor
Mitchell KapoorH.C. Wainwright
Success Rate19/19 ratings generated profit
100%
Average Return
+25.01%

Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +25.01% per trade.

AB3A Analyst Recommendation Trends

020406080Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for AB3A
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy65688
Buy21100
Hold1313151718
Sell44656
Strong Sell33455
total2826323537

In the current month, AB3A has received 8 Buy Ratings, 18 Hold Ratings, and 11 Sell Ratings. AB3A average Analyst price target in the past 3 months is 17.99.

AB3A Financial Forecast

CHF-5CHF-3CHF-1CHF1CHF3Q1 2026Q3 2026Q4 2026
HighCHF0.17
ConsensusCHF-0.30
LowCHF-1.30

AB3A Earnings Forecast

Next quarter’s earnings estimate for AB3A is -CHF 0.30 with a range of -CHF 1.30 to CHF 0.17. The previous quarter’s EPS was -CHF 0.23. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

CHF251.2MCHF341MCHF430.8MCHF520.6MCHF610.4MQ1 2026Q3 2026Q4 2026
HighCHF325M
ConsensusCHF296M
LowCHF251M

AB3A Sales Forecast

Next quarter’s sales forecast for AB3A is CHF 296.13M with a range of CHF 251.23M to CHF 325.12M. The previous quarter’s sales results were CHF 318.54M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

AB3A Stock Forecast FAQ

What is CH:AB3A’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is CHF17.99.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Sarepta Therapeutics a Buy, Sell or Hold?
Sarepta Therapeutics has a consensus rating of Hold, which is based on 3 buy ratings, 11 hold ratings and 4 sell ratings.
What is Sarepta Therapeutics’s share price target?
The average share price target for Sarepta Therapeutics is CHF17.99. This is based on 18 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF31.74, and the lowest forecast is CHF4.18. The average share price target represents a 0.00% increase from the current price of ―.
What do analysts say about Sarepta Therapeutics?
Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 18 Wall Street analysts.
How can I buy shares of Sarepta Therapeutics?
To buy shares of CH:AB3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.